Chondrodermatitis Nodularis Helicis (CNH) is a type of inflammatory condition that majorly affects the cartilage of ear and skin. It is also known as nodular chondrodermatitis, Winkler disease, and chondrodermatitis nodularis chronica helicis. A painful bump is witnessed on the cartilage of ear. It usually presents as a painful nodule which is surrounded by an area of erythema and often prevents the patient from sleeping on the affected side. Lesions are witnessed in both on the helix and on the antihelix.
This condition was first described by the dermatologist Winkler in 1915, who stated eight cases and later by Foerster, who again reported a further four cases. The exact occurrence of CNH remains unknown. This condition usually affects the helix of the pinna, though in some cases, the antihelix also may also be affected. For this reason, many researchers have suggested renaming the condition to chondrodermatitis nodularis auricularis.
Data Bridge Market Research analyses that the chondrodermatitis nodularis helicis market is expected to reach USD 658.4 million by 2030, which is USD 500 million in 2022, and is expected to undergo a CAGR of 3.50% during the forecast period 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Read Full Report Summary @ https://www.databridgemarketresearch.com/reports/global-chondrodermatitis-nodularis-helicis-market
North America is dominating the market in the forecast period because of the huge existence of large number of market players and growing clinical trials, well-developed healthcare sector and growing government support for R&D in this region. Asia-Pacific is considered the most lucrative period because of the increased incidence of diseases and rising healthcare expenditure.
Key players operating in the chondrodermatitis nodularis helicis market include:
Novartis AG (Switzerland)
Sanofi (France)
Pfizer Inc. (U.S.)
Johnson & Johnson Private Limited (U.S.)
Abbott (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Bausch Health Companies Inc. (Canada)
AstraZeneca (U.K.)
GSK plc (U.K.)
Takeda Pharmaceutical Company Limited (Japan)
Cadila Pharmaceuticals (India)
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.
Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475